A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

References

• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 Aug; 18(8):1254–61; PMID: 22842478; https://doi.org/10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012; 1(9):1557-76; PMID: 23264902; https://doi.org/10.4161/onci.22428
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005; 174(5):3080-6; PMID: 15728523; https://doi.org/10.4049/jimmunol.174.5.3080
   PubMed Web of Science ®Google Scholar
• Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med 2016; 4(14):266; PMID: 27563653; https://doi.org/10.21037/atm.2016.05.15
   PubMed Web of Science ®Google Scholar
• Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N. Identifying individual T Cell receptors of optimal avidity for tumor antigens. Front Immunol 2015; 6:582; PMID: 26635796; https://doi.org/10.3389/fimmu.2015.00582
   PubMed Web of Science ®Google Scholar
• Daniel C, Nolting J, von Boehmer H. Mechanisms of self-nonself discrimination and possible clinical relevance. Immunotherapy 2009; 1(4):631-44; PMID: 20582233; https://doi.org/10.2217/imt.09.29
   PubMed Web of Science ®Google Scholar
• Yutoku M, Fuji H, Grossberg AL, Pressman D. An experimental model for evaluation of factors in tumor escape from immunological attack. Cancer Res 1975; 35(3):734-9; PMID: 1116132
   PubMed Web of Science ®Google Scholar
• Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens. Hum Vaccin Immunother 2014; 10(11):3297-305; PMID: 25483660; https://doi.org/10.4161/hv.29475
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12(4):269-81; PMID: 22437939; https://doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Regner M. Cross-reactivity in T-cell antigen recognition. Immunol Cell Biol 2001; 79(2):91-100; PMID: 11349650; https://doi.org/10.1046/j.1440-1711.2001.00994.x
   PubMed Web of Science ®Google Scholar
• Chen HD, Fraire AE, Joris I, Brehm MA, Welsh RM, Selin LK. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat Immunol 2001; 2(11):1067-76; PMID: 11668342; https://doi.org/10.1038/ni727
   PubMed Web of Science ®Google Scholar
• Selin LK, Cornberg M, Brehm MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol 2004; 16(5):335-47; PMID: 15528078; https://doi.org/10.1016/j.smim.2004.08.014
   PubMed Web of Science ®Google Scholar
• Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R. Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. Front Immunol 2013; 4:485; PMID: 24421780; https://doi.org/10.3389/fimmu.2013.00485
   PubMed Web of Science ®Google Scholar
• Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19(9):395-404; PMID: 9745202; https://doi.org/10.1016/S0167-5699(98)01299-7
   PubMedGoogle Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520(7549):692-6; PMID: 25901682; https://doi.org/10.1038/nature14426
   PubMed Web of Science ®Google Scholar
• Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165(2):948-55; PMID: 10878370; https://doi.org/10.4049/jimmunol.165.2.948
   PubMed Web of Science ®Google Scholar
• Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA et al. Structure-based design of altered MHC Class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol 2013 Nov 15; 191(10), 5097-106; PMID:24108701; https://doi.org/10.4049/jimmunol.1300467
   PubMed Web of Science ®Google Scholar
• Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH et al. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. J Immunol 2014; 193(10):4803-13; PMID: 25311806; https://doi.org/10.4049/jimmunol.1400800
   PubMed Web of Science ®Google Scholar
• Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126(12):2658-63; PMID: 16946711; https://doi.org/10.1038/sj.jid.5700545
   PubMed Web of Science ®Google Scholar
• Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184(6):2207-16; PMID: 8976176; https://doi.org/10.1084/jem.184.6.2207
   PubMed Web of Science ®Google Scholar
• Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161(12):6970-6; PMID: 9862732
   PubMed Web of Science ®Google Scholar
• Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med 2016; 8(1):33; PMID: 27029192; https://doi.org/10.1186/s13073-016-0288-x
   PubMed Web of Science ®Google Scholar
• Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61(1):1-13; PMID: 19002680; https://doi.org/10.1007/s00251-008-0341-z
   PubMed Web of Science ®Google Scholar
• Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Keşmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013; 9(10):e1003266; PMID: 24204222; https://doi.org/10.1371/journal.pcbi.1003266
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC Class-I molecules. Annu Rev Immunol 1993; 11:213-44; PMID: 8476560; https://doi.org/10.1146/annurev.iy.11.040193.001241
   PubMed Web of Science ®Google Scholar
• Esquivel F, Yewdell J, Bennink J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 1992; 175(1):163-8; PMID: 1309852; https://doi.org/10.1084/jem.175.1.163
   PubMed Web of Science ®Google Scholar
• Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 2016; 5(4):e1105429; PMID: 27141389; https://doi.org/10.1080/2162402X.2015.1105429
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54(3):187-207; PMID: 15309328; https://doi.org/10.1007/s00262-004-0560-6
   PubMed Web of Science ®Google Scholar
• Wang R-F, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184(6):2207-16; PMID: 8976176; https://doi.org/10.1084/jem.184.6.2207
   PubMed Web of Science ®Google Scholar
• Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolić-Zugić J. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188(9):1553-61; PMID: 9802967; https://doi.org/10.1084/jem.188.9.1553
   PubMed Web of Science ®Google Scholar
• McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol 2006; 177(1):155-61; PMID: 16785510; https://doi.org/10.4049/jimmunol.177.1.155
   PubMed Web of Science ®Google Scholar
• Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications. Methods 2004; 34(4):436-43; PMID: 15542369; https://doi.org/10.1016/j.ymeth.2004.06.006
   PubMed Web of Science ®Google Scholar
• Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, Ekeruche J, Gostick E, Adams KJ, Skowera A et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185(4):2600-10; PMID: 20639478; https://doi.org/10.4049/jimmunol.1000629
   PubMed Web of Science ®Google Scholar
• Koch CP, Perna AM, Pillong M, Todoroff NK, Wrede P, Folkers G, Hiss JA, Schneider G. Scrutinizing MHC-I binding peptides and their limits of variation. PLoS Comput Biol 2013; 9(6):e1003088; PMID: 23754940; https://doi.org/10.1371/journal.pcbi.1003088
   PubMed Web of Science ®Google Scholar
• Messaoudi I, LeMaoult J, Nikolic-Zugic J. The mode of ligand recognition by two peptide: MHC class I-specific monoclonal antibodies. J Immunol 1999; 163(6):3286-94; PMID: 10477598
   PubMed Web of Science ®Google Scholar
• Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002; 188:81-96; PMID: 12445283; https://doi.org/10.1034/j.1600-065X.2002.18808.x
   PubMed Web of Science ®Google Scholar
• Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54(6):777-85; PMID: 3261634; https://doi.org/10.1016/S0092-8674(88)91043-4
   PubMed Web of Science ®Google Scholar
• De Bruijn ML, Schumacher TN, Nieland JD, Ploegh HL, Kast WM, Melief CJ. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol 1991; 21(12):2963-70; PMID: 1660811; https://doi.org/10.1002/eji.1830211210
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193(4):1920-30; PMID: 25024381; https://doi.org/10.4049/jimmunol.1400948
   PubMed Web of Science ®Google Scholar
• Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15(2):378-85; PMID: 17235317; https://doi.org/10.1038/sj.mt.6300031
   PubMed Web of Science ®Google Scholar
• Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012; 20(11):2076-86; PMID: 22828500; https://doi.org/10.1038/mt.2012.137
   PubMed Web of Science ®Google Scholar